.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Deloitte
Cipla
McKinsey
UBS
Dow
Fish and Richardson
QuintilesIMS
Colorcon
Chinese Patent Office

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,435,944

« Back to Dashboard

Which drugs does patent 8,435,944 protect, and when does it expire?


Patent 8,435,944 protects AXIRON and is included in one NDA. There has been one Paragraph IV challenge on Axiron.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,435,944

Title:Method and composition for transdermal drug delivery
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
Inventor(s): Dipietro; Tony (Victoria, AU), Humberstone; Andrew (Victoria, AU), Gonda; Igor (South Yarra, AU), Watkinson; Adam (Victoria, AU), Setiawan; Kerrie (Victoria, AU), Wilkins; Nina (Victoria, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:11/445,463
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010ATRXYesYes8,435,944► Subscribe A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,435,944

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2005902902Jun 03, 2005

Non-Orange Book Patents for Patent: 8,435,944

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,993,520Method and composition for transdermal drug delivery► Subscribe
9,180,194Method and composition for transdermal drug delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,435,944

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006254742► Subscribe
Australia2011202787► Subscribe
BrazilPI0611134► Subscribe
Canada2610708► Subscribe
China101212975► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Chubb
Boehringer Ingelheim
Argus Health
Mallinckrodt
Cantor Fitzgerald
US Department of Justice
Fuji
AstraZeneca
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot